UBS lowered the firm’s price target on Bath & Body Works to $17 from $32 and keeps a Neutral rating on the shares. Bath & Body Works’ Q3 report is likely a negative catalyst for the stock, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBWI:
- Cautious Hold Rating for Bath & Body Works Amid Strategic Shifts and Underperformance
- Bath & Body Works price target lowered to $26 from $32 at BofA
- Bath & Body Works price target lowered to $25 from $33 at Wells Fargo
- Bath & Body Works price target lowered to $21 from $35 at Citi
- Bath & Body downgraded to Market Perform from Outperform at Telsey Advisory